For years, prostate cancer risk has been measured by PSA, Gleason score & stage, and diagnosis & treatment protocols have remained pretty much the same. The fact is, traditional assessment doesn’t provide all of the information needed to appropriately stratify prostate cancer risk and weigh possible treatment options.
Let's take a look at a Prolaris case study:
PATIENT CLINICAL PROFILE
Patient Age: 58
PSA Prior to Biopsy: 3.3
Clinical T-Stage: T1c
Biopsy: 14% Positive Cores (2/14)
Gleason Score: 3+3
AUA Risk Classification: Low
Given this patient's clinical features, what course(s) of action would you consider? The Prolaris Score can help you identify those patients with less or more aggressive prostate cancer that might not be as easily visible using Gleason Score and PSA alone.
For this patient, the planned management was to go on active surveillance.
THE PROLARIS SCORE
The Prolaris Score for this patient came back as 4.3 which indicated...
THE PROLARIS® TEST
Prolaris® is a prognostic test developed by Myriad Genetic Laboratories, which directly measures tumor cell growth characteristics for stratifying the risk of disease progression in prostate cancer patients. The 46-gene expression signature includes cell cycle progression genes selected based upon correlation with prostate tumor cell proliferation:
- low gene expression associated with a low risk of disease progression
- high gene expression associated with disease progression
Prolaris testing combines traditional risk factors with a molecular assessment of the aggressiveness of an individual patient’s cancer to deliver a more informed risk assessment. So you and your patient can be confident when choosing a course of management.
PROLARIS WILL:
- Provide a 10-year prostate cancer-specific mortality risk
- Deliver a personalized assessment of risk
- Add confidence in disease management decisions
